Evolus Expands International Presence With Launch Of Nuceiva In Spain
- Launching in one of the five largest aesthetic toxin injectable markets in Europe1 as part of the company's geographic expansion strategy
- Evolus to provide Nuceiva® for direct order and delivery to Spanish medical aesthetics healthcare professionals
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company focused on building an aesthetic portfolio, has commercially launched Nuceiva® (botulinum toxin type A) in Spain. The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals.